Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.30 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474611 | 0.82 | LMNA (0.36) | SMN1; SMN2KCNK3ALDH1A1HPGD | |
| SCHEMBL21471613 | 0.81 | NOTUM (0.32) | SMN1; SMN2TP53GRM2KDM4EALDH1A1 | |
| SCHEMBL21471717 | 0.81 | MAPK14 (0.41) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL21474620 | 0.81 | MAPK14 (0.41) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL21474623 | 0.80 | MAPT (0.36) | KCNK3KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21471714 | 0.78 | CHRM2 (0.38) | KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL20599068 | 0.78 | NOTUM (0.46) | KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL20619490 | 0.76 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL21471675 | 0.75 | ALDH1A1 (0.47) | SMN1; SMN2KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL21471683 | 0.74 | CHRM2 (0.36) | KDM4EALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | SCD 758/4885SMN1; SMN2 382/4885TP53 3359/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | SCD 758/4885SMN1; SMN2 382/4885TP53 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.